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Abstract
Background: Staphylococcus aureus is an important nosocomial bacterium that is responsible for a number of  infections that may 
be fatal. The treatment of  such infections is limited by emergence of  antibiotic resistance. Targeting virulence of  Staphylococcus 
aureus may provide an alternative option to antibiotic that may bypass the emergence of  resistant strains due to lack of  stress on 
viability. 
Objectives: Investigation of  the ability of  glyceryl trinitrate (GTN) to inhibit staphyloxanthin, biofilm and tolerance to oxidative 
stress.
Methods:  The disk sensitivity method was used to detect the methicillin resistance of  Staphylococcus aureus. The effect of  sub-in-
hibitory concentration of  GTN on biofilm formation, staphyloxanthin production and tolerance to oxidative stress was evaluat-
ed. Molecular docking study was used to investigate the ability of  GTN to bind to dehydrosqualene synthase enzyme. 
Results: GTN showed a significant inhibition of  biofilm, staphyloxanthin and tolerance to oxidative stress. In the molecular 
docking study, it was found that GTN could bind to dehydrosqualene synthase enzyme by hydrogen bonding,electrostatic in-
teraction and pi-cation interaction. 
Conclusion: The present study revealed the ability of  GTN to serve as a potential anti-virulence candidate for attenuation of  
S. aureus pathogenicity.
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Unlike the large number of  antibiotics discovered or syn-
thesized in the twentieth century,the number of  antibi-
otics developed in the current century is much lower1. 
Moreover, antibiotics prescribed for treatment of  infec-
tions over many years led to the emergence of  antibiotic 
resistant strains of  Staphylococcus aureus due to the stress 
exerted on bacterial growth2,3. One approach of  combat-
ing antibiotic resistance is based on disarming the bacte-
rial virulence factors that enable the bacteria to cause dis-
ease. This strategy avoids the bacterial cell viability-stress 
induced emergence of  resistance and, as a result, can be 
helpful in preventing or treating infections3,4.
S. aureus is a human pathogen that is responsible for sev-
eral nosocomial and community-acquired infections such 
as cutaneous and soft-tissue infections in addition to dan-
gerous systemic infection5-7. Methicillin-resistant S. aureus 
(MRSA) is a great public-health problem8-10. MRSA are 
resistant to the majority of  available antibiotics and the 
treatment options are very few11. 
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In order to develop multidrug resistance, it employs an 
arsenal of  virulence factors that help it evade the host 
immune response. Staphyloxanthin; the golden yellow ca-
rotenoid pigment is one of  such virulence factors.  It acts 
as a reducing agent to neutralize the reactive oxygen spe-
cies (ROS) produced by neutrophils and macrophages12, 
13. Without staphyloxanthin, S. aureus is defective in infec-
tivity and is liable to be attacked by neutrophils with the 
subsequent inability to cause infection in a mouse mod-
el1,5,14.
Staphylococcus aureus has the ability to form biofilms either 
on human tissues or implants, resulting in chronic infec-
tions that are difficult to treat due to extreme resistance 
to antibiotics15. Inhibition of  staphyloxanthin was previ-
ously investigated16.
Glyceryl trinitrate (GTN) is a drug used in treatment of  
hypertension17. GTN was able to inhibit biofilms formed 
by Staphylococcus aureus, Staphylococcus epidermidis, Pseudomo-
nas aeruginosa and candida albicans18. GTN is approved by 
FDA for topical treatment of  anal fissures at concentra-
tions up to 0.4%19.
The objective of  this study was to identify the potential 
inhibitory activity of  glyceryl trinitrate against staphylox-
anthin and biofilm formation.
 
Materials and methods
Media and chemicals 
The media used in this study were Mueller Hinton broth, 
Mueller Hinton agar, Tryptone soya broth and Tryptone 
soya agar. These media in addition to methicillin antibi-
otic disk were purchased from Oxoid (Hampshire, UK). 
Glyceryl trinitrate was obtained from POHL-Boskamp, 
Gmbh &Co., Hohenlockstedt, Germany (Stock solution 
of  1 mg/ml). Other chemicals were of  pharmaceutical 
grade. 
Bacterial strains
Staphylococcus aureus ATCC 6538 strain was kindly provided 
by the Department of  Microbiology, Faculty of  Pharma-
cy, Mansoura University. A clinical isolate of  Staphylococcus 
aureus (SA1) was isolated from a patient with a surgical 
site infection at Zagazig University Surgery Department 
and identified by The MALDI-TOFF apparatus at the 
Clinical Pathology Department, Faculty of  Medicine, Za-
gazig University. 
Antimicrobial susceptibility testing
Antibiotic susceptibility of  SA1 was tested against methi-
cillin using the Kirby-Bauer standard disk diffusion meth-
od according to CLSI guidelines20. 
Müeller-Hinton broth (5 ml) was inoculated with three to 
five well-isolated colonies from an overnight agar plate 
culture and the broth culture was incubated at 37°C with 
shaking for 4 to 6 hours until a turbidity of  a 0.5 McFar-
land standard was achieved or exceeded. Sterile broth was 
used to adjust the turbidity to achieve turbidity matching 
that of  a 0.5 McFarland standard. A sterile cotton swab 
was moistened with the bacterial suspension and pressed 
on the inside wall of  the tube to remove excess inocu-
lum. The swab was streaked both over the surface of  the 
Mueller Hinton agar plate and around the agar rim. The 
antibiotic disks were put on the inoculated plate and gen-
tly pressed into the agar and the plates were incubated at 
37°C for 18 hours. The inhibition zones diameters were 
measured, and interpreted as resistant, intermediate or 
susceptible according to CLSI21.
Determination of  Minimum Inhibitory Concentra-
tion (MIC)
The agar dilution method was used in determination 
of  the minimum inhibitory concentration of  GTN ac-
cording to the Clinical Laboratory and Standards Insti-
tute Guidelines (CLSI)20. The tested strain was incubated 
overnight in tryptone soya broth (TSB) and the suspen-
sion was diluted with Mueller-Hinton broth in order to 
prepare a suspension with a turbidity approximating that 
of  0.5 McFarland Standard. The suspension was further 
diluted with sterile saline (1:10). By using a micropipette, 
a standardized inoculum (approximately 104 CFU per 
spot) was spotted on the surface of  Mueller-Hinton agar 
plates containing different GTN concentrations and con-
trol plate without GTN. The MIC of  GTN was the low-
est concentration that inhibits growth on the plate after 
incubation at 37 °C for 20 hours.
Assay of  biofilm formation and inhibition 
In order to test the biofilm formation capacity of  S. au-
reus, the modified method of  Stepanovic et al.22 was used. 
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From overnight cultures of  the tested strain, bacterial sus-
pension with a density of  1 × 106 CFU/ ml was prepared 
by dilution with TSB. The bacterial suspension was deliv-
ered in aliquots (100μl) to a sterile microtiter plate wells 
that was incubated for 48 hours at 37°C. The non-adher-
ent cells were discarded by removal of  the suspensions 
from the microtiter plate wells and the wells were then 
washed 3 times using sterile phosphate buffered saline. 
The biofilm cells were fixed by 99% methanol for 20 min-
utes and the wells were stained with crystal violet (1%) 
for another 20 minutes followed by washing with distilled 
water for removing excess dye.
After leaving the plate to air dry, the dye was dissolved by 
33% glacial acetic acid and the contents of  the microti-
ter plate were transported to another plate for measuring 
the optical densities at 590 nm using spectrofluorimeter 
(Biotek, USA). 
The cut-off  optical density (ODc) was determined as 
three times standard deviations above the mean OD of  
the negative control. Following the criteria of  Stepanovic 
et al.22, S. aureus strain was non-biofilm producer (OD less 
than ODc), weak biofilm producer (OD between ODc 
and 2x ODc), moderate biofilm producer (OD between 
2x ODc and 4x ODc), or strong biofilm producer (OD 
more than 4x ODc).
In order to investigate the biofilm inhibiting activity of  
GTN, the previous procedure was repeated, but in the 
absence and presence of  0.125 mg/ml of  GTN and bio-
film inhibition was calculated by the following formula
% of  biofilm inhibition = (OD without GTN-OD with 
GTN)/ OD without GTN
 
Microscopic visualization of  biofilm inhibition
S. aureus was grown in TSB and incubated overnight at 
37°C and the optical density was adjusted to reach 1 at 
600 nm. Sterile glass cover slips were placed inside in 50 
ml falcon tubes containing fresh media and inoculated 
with the bacterial suspension in the presence and absence 
of  0.125 mg/ml of  GTN. The biofilms were allowed 
to form for 48 hours at 37°C and the cover slips were 
washed and stained with crystal violet (1%) and examined 
under the light microscope using the high power (400X 
magnification)22.
Staphyloxanthin assay
The ability of  GTN to reduce the production of  the 
golden yellow staphyloxanthin pigment was investigat-
ed1.  For qualitative assay, overnight culture of  the tested 
strains in MHB was prepared. The bacterial suspensions 
were diluted 1:100 in fresh MHB containing GTN and 
control tubes without GTN were prepared in the same 
way. The tubes were incubated for 24 hours at 37 °C with 
shaking at 250 rpm. The pellets were collected by centrif-
ugation at 16,600×g for 10 min and the pellets were pho-
tographed and the golden yellow pigment was compared 
in treated and untreated samples.
For quantitative assay, the pellets recovered were resus-
pended in methanol (0.2 ml) by vortexing, and the re-
sultant mixture was heated at 55°C for 30 minutes for 
pigment extraction. The extracted pigment was separated 
by centrifugation at 16,600 xg for 10 minutes and the ex-
traction process was repeated thrice. The absorbance of  
the extracted pigment solutions was measured at 465nm 
using spectrofluorimeter (Biotek, USA). 
 
Sensitivity to oxidative stress
To investigate the interfering capacity of  GTN with re-
sistance to oxidative stress, the modified disk assay meth-
od of  Hassett et al.23 was used. S. aureus was cultured in 
TSB and incubated overnight. Aliquots of  0.1 ml were 
spread onto the surface of  Tryptone soya agar plates with 
and without 0.125 mg/ml of  GTN. Sterile paper disks (6 
mm) were placed on the surface of  Tryptone soya agar 
plates and 10 μl of  hydrogen peroxide (1.5%) was added 
to them. The inhibition zones were measured after incu-
bating the plates for 24 hours at 37°C.
Docking study
The crystal structure of  the C30 carotenoid dehydro-
squalene synthase from Staphylococcus aureus was retrieved 
from Protein Data Bank (PDB ID: 2ZCQ)24. Docking 
study was carried out on glyceryl trinitrate (GTN) into 
the receptor active site using Molegro Virtual Docker 
(MVD Version 6.0). GTN was drawn into Marvin Sketch 
V5.11.525. The most energetically favored conformer was 
exported as mol2 file format for docking. The optimal ge-
ometry of  the ligand was determined during the docking 
process. The search area was set to be 13 Å from the 
center of  the active site. MolDock optimizer algorithm 
was chosen to perform docking process with 10 runs per 
ligand, 150 population size, 4000 max iteration and 8 pos-
es for each ligand. MolDock score26 was used as scoring 
function. Finally, the top returned poses were chosen for 
analysis. 
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Statistical analysis
One Way ANOVA followed by Newman-Keuls Multiple 
Comparison Test, Graph Pad Prism5 was used to investi-
gate the significance of  the inhibitory activities of  GTN 
against staphyloxanthin, oxidative stress and biofilm for-
mation. P values <0.05 were considered statistically sig-
nificant.
Results 
Methicillin resistance of  SA1and antibacterial activi-
ty of  GTN against S. aureus
The clinical isolate of  S. aureus SA1 was found to be re-
sistant to methicillin. GTN inhibited the growth of  S. au-
reus at 0.5 mg/ml. The inhibitory activity of  GTN against 
biofilm formation, staphyloxanthin production and resis-
tance to oxidative stress was evaluated at ¼ MIC (0.125 
mg/ml).
GTN inhibits biofilm formation
The standard strain S. aureus ATCC 6538 is well-known 
as a strong biofilm forming strain. The clinical isolate was 
also strong biofilm producer as its OD is 0.806>0.256 
(4X ODc). GTN exerted a significant biofilm inhibition 
in both strains.   Biofilm of  S. aureus ATCC 6538 was 
inhibited by 69.16%, while that of  the clinical isolate was 
reduced by 52.64% (Fig. 1). This biofilm inhibiting activ-
ity was further confirmed by microscopical examination 
of  biofilms formed on glass cover slips in the presence 
and absence of  GTN and examined with the light mi-
croscope. Much fewer scattered cells were found in the 
sample treated with GTN. 
 
Figure 1. Inhibition of biofilm formation of S. aueus by ¼ MIC of GTN. *,  
significant P < 0.05. Microscopic images of biofilm formed by S. aureus  
ATCC 6538 under the light microscope (X400) in the treated culture (right) and untreated (left). 
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GTN inhibits staphyloxanthin production
The golden yellow color of  staphyloxanthin enables the 
visual inspection of  its production. The cell pellets sep-
arated from the GTN treated samples showed a remark-
able reduction in staphyloxanthin production (Fig. 2). 
This was confirmed by quantitative assay in which a sig-
nificant inhibitory activity of  staphyloxanthin was found 
in the GTN treated samples as compared to the control 
samples. The staphyloxanthinproduction was reduced by 
63.37% in S. aureus ATCC 6538 and by 70.98% in the 
clinical isolate SA1.
 
Figure 2. Inhibition of Staphyloxanthin production by ¼ MIC of GTN. *, significant P < 0.05. 
GTN decreases the tolerance against oxidative stress
The inhibitory activity of  GTN against the tolerance to 
oxidative stress was investigated by testing the augmen-
tation of  hydrogen peroxide on the growth of  S. aureus 
by GTN. GTN showed a significant decrease in the tol-
erance to oxidative stress by 36.94% in S. aureus ATCC 
6538 and 42.6% in the clinical isolate SA1 (Fig. 3).
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Figure 3. Reduction of tolerance to oxidative stress by ¼ MIC of GTN. *, significant P < 0.05. 
Docking study
The binding mode of  GTN was studied using molecu-
lar docking study. GTN has nine hydrogen bonds with 
Arg45, Tyr129, Gln165, Asn168, Val 133 and Tyr248 elec-
trostatic interaction with Arg45 and Asp48 and pi-cation 
interaction of  the nitrogen atom  with Tyr183 resulting 
in docking score of  -99.658 (Fig. 4). GTN can effectively 
interact with the dehydrosqualene synthase active site.    
 
Figure 4. The Molecular docking of GTN into the active site of dehydrosqualene  
synthase 3D (Left) and 2D schematic view of the binding (Right). 
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Discussion 
The rate of  methicillin resistance among S. aureus reached 
a peak in such a way that the mortality rate in the U.S. 
due to invasive MRSA exceeds that due to AIDS27,28. This 
problem needs urgent action for development of  other 
therapeutic approaches29. One of  these approaches is the 
search for anti-virulence drugs. In our study, GTN could 
inhibit the growth of  S. aureus 6538 and the clinical iso-
late SA1 at 0.5 mg/ml. The anti-virulence potential of  
GTN was investigated at 0.125 mg/ml. The capability 
of  S. aureus to produce virulence factors is linked to its 
pathogenicity. These factors include biofilm formation 
and the antioxidant pigment staphyloxanthin30.
Staphyloxanthin protects S. aureus from phagocytosis. It 
was reported that the strains of  S. aureus that are deficient 
in staphyloxanthin production are sensitive to killing by 
reactive oxygen species produced by neutrophils and are 
defective in their ability to form skin abscesses1. 
GTN exerted biofilm inhibiting activity that ranged be-
tween 52.64% and 69.16%. The anti-biofilm activity 
of  GTN against S. aureus was previously reported as a 
catheter lock solution in combination with ethanol and 
citrate31. The anti-biofilm activity of  GTN was further 
explored by microscopic examination of  biofilms formed 
on glass cover slips treated and untreated with GTN. The 
treated sample showed very few scattered cells in contrast 
to the dense compact cells in the control sample. 
In this study, the biological activity of  GTN on the pro-
duction of  staphyloxanthin pigment was inspected by ex-
traction of  the pigment from GTN treated and untreated 
cells. The pigment in GTN treated cells was reduced to 
the range of  63.37% to 70.98%. Furthermore, the in vitro 
susceptibility to oxidants was tested by investigation of  
the augmentation of  the sensitivity to hydrogen peroxide. 
The susceptibility to hydrogen peroxide was increased be-
tween 36.94% and 42.6%. This may be due to blockade 
of  staphyloxanthin pigment. This was in accordance with 
the finding of  Liu et al.32 
Dehydrosqualene synthase is an enzyme that is involved 
in the first step of  staphyloxanthin biosynthesis13. As a re-
sult, the interaction of  GTN with dehydrosqualene syn-
thase enzyme was investigated. Docking study was made 
to identify the ability of  GTN to bind to the active site of  
dehydrosqualene synthase. GTN was found to attach to 
the enzyme by a combination of  hydrogen bonds, elec-
trostatic interaction and pi-cation interaction. In other 
terms, GTN may be a competitive inhibitor of  this en-
zyme leading to inhibition of  staphyloxanthin synthesis.
Interestingly, the anti-virulence activity of  GTN was ex-
erted at 0.125 mg/ml, a much lower concentration of  
GTN that is approved by FDA for topical use (up to 
0.4% or 4 mg/ml).
Repurposing GTN as an anti-virulence agent is advan-
tageous. It is an FDA approved whose pharmacological 
and toxicological properties are well-known. Moreover, 
using FDA approved drug saves the high costs and short-
ens the long development times to produce new anti-
microbials or virulence inhibitors33. Our previous stud-
ies showed that GTN is a potent inhibitor of  quorum 
sensing and virulence in Pseudomonas aeruginosa and Serra-
tia marcescens34,35. The rationale of  repurposing drugs for 
use as anti-virulence agents against Stapylococcus aureus was 
previously reported. Thus, diflunisal; the non-steroidal 
anti-inflammatory drug was reported as a potent inhibi-
tor of  virulence in USA300 strain of  methicillin-resistant 
S. aureus36. However, further clinical trials are necessary 
to test the clinical efficacy of  GTN in laboratory animals 
and human volunteers. 
Conclusion
GTN is a potential anti-virulence agent that can be useful 
in the treatment of  S. aureus topical infections. 
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